Grimm Martin, Feyen Oliver, Coy Johannes F, Hofmann Heiko, Teriete Peter, Reinert Siegmar
Department of Oral and Maxillofacial Surgery, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Zyagnum AG, 64319 Pfungstadt, Germany.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. doi: 10.1016/j.oooo.2015.10.024. Epub 2015 Nov 4.
Monocytes/macrophages are regarded as the first line of defense in tumors. Therefore, analyzing monocyte subtypes in oral squamous cell carcinoma (OSCC) may be of value in disease monitoring and to explore immunotherapeutic strategies for cancer patients.
Circulating peripheral blood CD14+/CD16+ monocyte-derived macrophages (MDMs) were evaluated in OSCC patients with oral squamous cell carcinoma (n = 44) compared with controls (n = 85). Moreover, epitope detection in monocytes (EDIM) technology was used to detect biomarkers Apo10 and transketolase-like-1 in CD14+/CD16+ MDMs.
Compared with controls, no significant (P = .3646) difference (control group 9.8%, OSCC group 8.8%) in CD14+/CD16+ MDM were noted in OSCC. However, EDIM-Apo10 and EDIM-TKTL1 scores detected in the CD14+/CD16+ MDMs were increased in OSCC compared with controls (P < .0001).
Analyzing CD14+/CD16+ MDMs represents a stable cell population for detecting biomarkers in cancer disease monitoring.
单核细胞/巨噬细胞被视为肿瘤的第一道防线。因此，分析口腔鳞状细胞癌（OSCC）中的单核细胞亚型可能对疾病监测以及探索癌症患者的免疫治疗策略具有价值。
对44例口腔鳞状细胞癌患者的循环外周血CD14+/CD16+单核细胞衍生巨噬细胞（MDM）进行评估，并与85例对照进行比较。此外，采用单核细胞表位检测（EDIM）技术检测CD14+/CD16+ MDM中的生物标志物Apo10和转酮醇酶样-1。
与对照组相比，OSCC患者CD14+/CD16+ MDM无显著差异（P = 0.3646）（对照组9.8%，OSCC组8.8%）。然而，与对照组相比，OSCC患者CD14+/CD16+ MDM中检测到的EDIM-Apo10和EDIM-TKTL1评分升高（P < 0.0001）。
分析CD14+/CD16+ MDM是癌症疾病监测中检测生物标志物的稳定细胞群体。
